Literature DB >> 24824040

Common target genes of palatal and gingival fibroblasts for EMD: the microarray approach.

R Gruber1, A Stähli, R J Miron, D D Bosshardt, A Sculean.   

Abstract

BACKGROUND AND
OBJECTIVE: Connective tissue grafts are frequently applied, together with Emdogain(®) , for root coverage. However, it is unknown whether fibroblasts from the gingiva and from the palate respond similarly to Emdogain. The aim of this study was therefore to evaluate the effect of Emdogain(®) on fibroblasts from palatal and gingival connective tissue using a genome-wide microarray approach.
MATERIAL AND METHODS: Human palatal and gingival fibroblasts were exposed to Emdogain(®) and RNA was subjected to microarray analysis followed by gene ontology screening with Database for Annotation, Visualization and Integrated Discovery functional annotation clustering, Kyoto Encyclopedia of Genes and Genomes pathway analysis and the Search Tool for the Retrieval of Interacting Genes/Proteins functional protein association network. Microarray results were confirmed by quantitative RT-PCR analysis.
RESULTS: The transcription levels of 106 genes were up-/down-regulated by at least five-fold in both gingival and palatal fibroblasts upon exposure to Emdogain(®) . Gene ontology screening assigned the respective genes into 118 biological processes, six cellular components, eight molecular functions and five pathways. Among the striking patterns observed were the changing expression of ligands targeting the transforming growth factor-beta and gp130 receptor family as well as the transition of mesenchymal epithelial cells. Moreover, Emdogain(®) caused changes in expression of receptors for chemokines, lipids and hormones, and for transcription factors such as SMAD3, peroxisome proliferator-activated receptor gamma and those of the ETS family.
CONCLUSION: The present data suggest that Emdogain(®) causes substantial alterations in gene expression, with similar patterns observed in palatal and gingival fibroblasts.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Emdogain; enamel matrix derivative; fibroblasts; gingiva; microarray; palate

Mesh:

Substances:

Year:  2014        PMID: 24824040     DOI: 10.1111/jre.12186

Source DB:  PubMed          Journal:  J Periodontal Res        ISSN: 0022-3484            Impact factor:   4.419


  6 in total

1.  Does enamel matrix derivative application improve clinical outcomes after semilunar flap surgery? A randomized clinical trial.

Authors:  Isabela Lima França-Grohmann; João Paulo Menck Sangiorgio; Manuela Rocha Bueno; Renato Corrêa Viana Casarin; Karina Gonzáles Silvério; Francisco Humberto Nociti; Márcio Zaffalon Casati; Enilson Antonio Sallum
Journal:  Clin Oral Investig       Date:  2018-06-12       Impact factor: 3.573

2.  Enamel Matrix Derivative Decreases Pyroptosis-Related Genes in Macrophages.

Authors:  Mariane Beatriz Sordi; Ariadne Cristiane Cabral da Cruz; Layla Panahipour; Reinhard Gruber
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

3.  RNAseq of TGF-β receptor type I kinase-dependent genes in oral fibroblast exposed to milk.

Authors:  Layla Panahipour; Dariush Mehdipour Moghaddam; Jila Nasirzade; Zahra Kargarpour; Reinhard Gruber
Journal:  BMC Oral Health       Date:  2021-11-16       Impact factor: 3.747

4.  TGF-β Signalling Mediates the Anti-Inflammatory Activity of Enamel Matrix Derivative In Vitro.

Authors:  Layla Panahipour; Mariane Beatriz Sordi; Zahra Kargarpour; Reinhard Gruber
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

5.  Novel biological activity of ameloblastin in enamel matrix derivative.

Authors:  Sachiko Kuramitsu-Fujimoto; Wataru Ariyoshi; Noriko Saito; Toshinori Okinaga; Masaharu Kamo; Akira Ishisaki; Takashi Takata; Kazunori Yamaguchi; Tatsuji Nishihara
Journal:  J Appl Oral Sci       Date:  2015 Jan-Feb       Impact factor: 2.698

6.  Emdogain-regulated gene expression in palatal fibroblasts requires TGF-βRI kinase signaling.

Authors:  Alexandra Stähli; Dieter Bosshardt; Anton Sculean; Reinhard Gruber
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.